Novonesis (NVZMY)
OTHER OTC:NVZMY
Want to see NVZMY full AI Analyst Report?
NVZMY Stock Chart & Stats
$63.41
-$0.61(-1.09%)
At close: 4:00 PM EST
$63.41
-$0.61(-1.09%)
Day’s Range― - ―
52-Week Range$52.70 - $75.69
Previous CloseN/A
Volume8.66K
Average Volume (3M)1.56K
Market Cap
$28.03B
Enterprise Value$27.06B
Total Cash (Recent Filing)$329.74M
Total Debt (Recent Filing)$3.22B
Price to Earnings (P/E)221.3
Beta0.16
Next Earnings
Aug 20, 2026EPS Estimate
0.77Next Dividend Ex-DateN/A
Dividend Yield1.51%
Share Statistics
EPS (TTM)3.24
Shares Outstanding414,555,050
10 Day Avg. Volume2,114
30 Day Avg. Volume1,559
Financial Highlights & Ratios
PEG Ratio12.64
Price to Book (P/B)15.45
Price to Sales (P/S)40.34
P/FCF Ratio223.41
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue2.44
Enterprise Value/Gross Profit4.67
Enterprise Value/Ebitda7.98
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.38
Revenue Forecast (FY)$5.18B
Bulls Say, Bears Say
Bulls Say
Diversified Biosolutions Across Food, Home Care, Ag And Industrial MarketsA broad portfolio selling enzymes, strains and cultures into multiple end markets reduces reliance on any single cycle. Durable B2B relationships, technical service embedment and repeat production demand support steady recurring revenue and multiple structural growth avenues over years.
Robust Trailing‑12‑month Cash Generation And FCF ConversionStrong TTM operating cash flow and free cash flow indicate reliable internal funding for growth, capacity builds and M&A. High cash conversion versus net income supports balance‑sheet resilience, reinvestment and shareholder returns while reducing dependence on external financing.
High And Resilient Margins With Reiterated Full‑year GuidanceSustained high gross and EBITDA margins reflect pricing power, product differentiation and operational scale in specialty biosolutions. Management reaffirming margin guidance despite FX and cost headwinds suggests structural margin resilience and effective cost and synergy realization.
Bears Say
Historical Volatility In Annual Results And Cash FlowsMaterial swings in annual revenue, margins and cash flow reduce forecasting visibility and increase execution risk. Such volatility complicates multi‑year planning, raises working‑capital sensitivity and can amplify the impact of cyclical end‑market slowdowns on returns and investment plans.
Notable Leverage Spike In 2025 Despite Low TTM Debt LevelsA recent surge in leverage in 2025, even if TTM debt appears low, signals episodic balance‑sheet strain or financing for acquisitions/capex. Higher leverage can constrain strategic flexibility, increase refinancing and interest risk, and reduce headroom for downturns or further M&A.
Planned CapEx Step‑up And Operating‑expense Ramp Increase Near‑term Cash NeedsManagement plans a material CapEx increase plus a commercial opex ramp to scale capacity and go‑to‑market resources. While strategic, higher sustained investment and expense ratios elevate funding needs, can compress free cash flow in the medium term and raise execution and timing risk on returns.
Novonesis News
NVZMY FAQ
What was Novonesis’s price range in the past 12 months?
Novonesis lowest stock price was $52.70 and its highest was $75.69 in the past 12 months.
What is Novonesis’s market cap?
Novonesis’s market cap is $28.03B.
When is Novonesis’s upcoming earnings report date?
Novonesis’s upcoming earnings report date is Aug 20, 2026 which is in 88 days.
How were Novonesis’s earnings last quarter?
Novonesis released its earnings results on May 05, 2026. The company reported $0.674 earnings per share for the quarter, missing the consensus estimate of $0.816 by -$0.142.
Is Novonesis overvalued?
According to Wall Street analysts Novonesis’s price is currently Overvalued.
Does Novonesis pay dividends?
Novonesis pays a Semiannually dividend of $0.35 which represents an annual dividend yield of 1.51%. See more information on Novonesis dividends here
What is Novonesis’s EPS estimate?
Novonesis’s EPS estimate is 0.77.
How many shares outstanding does Novonesis have?
Novonesis has 414,555,050 shares outstanding.
What happened to Novonesis’s price movement after its last earnings report?
Novonesis reported an EPS of $0.674 in its last earnings report, missing expectations of $0.816. Following the earnings report the stock price went down -0.05%.
Which hedge fund is a major shareholder of Novonesis?
Currently, no hedge funds are holding shares in NVZMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novonesis Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.36%
12-Months-Change
Fundamentals
Return on Equity
5.52%
Trailing 12-Months
Asset Growth
17.05%
Trailing 12-Months
Company Description
Novonesis
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers baking, beverages, dairy, starch, and protein solutions for the food and beverage industry; laundry, dishwashing, and professional cleaning solutions for the household care industry; agriculture solutions, including crop production, and animal health and nutrition solutions; bioyield and biocontrol solutions for crops; and grain and technical processing solutions, as well as bio energy solutions for liquefaction, saccharifaction, fermentation, fiber conversion, and biomass conversion. It also provides textile solutions, such as biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing solutions. In addition, the company offers solutions for pulp & paper, including fiber modification, bleach boosting, deposit control, starch modification, and deinking; leather solutions comprising acid bating, area expansion, bating, degreasing, soaking, and unhairing and liming; and water and waste management solutions, which consist of bioaugmentation, biogas, and sludge management. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis, as well as rTrypsin for cell culture; and human health and protein solutions. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
NVZMY Company Deck
NVZMY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a positive operational and financial start to 2026: solid 7% organic growth, improved gross margin (+120 bps), strong cash flow and EPS (+8%), successful financing and ongoing integration synergies from the Feed Enzyme Alliance. Notable near-term headwinds include currency impacts, higher operating expenses and a temporary CapEx step-up, plus segment-specific softness in North American probiotics and timing-driven declines in tech/plant. Management maintains confident full-year guidance (5%–7% organic growth; 37%–38% adj. EBITDA margin) and reiterates medium-term targets, indicating that positives (growth, margins, cash, strategic M&A and product launches) materially outweigh the transitory negatives.View all NVZMY earnings summariesNVZMY Revenue Breakdown
28.53% Household Care
24.83% Bioenergy
22.07% Food, Beverages & Human Health
12.82% Grain & Tech Processing
11.75% Agriculture & Animal Health
Technical Analysis
International Flavors & Fragrances
―
LyondellBasell
―
PPG Industries
―
RPM International
―
DuPont de Nemours
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---